Abstract
We report the emergence of cefiderocol resistance in a blaOXA-72 carbapenem-resistant Acinetobacter baumannii isolate from a sacral decubitus ulcer. Cefiderocol was initially used; however, a newly approved sulbactam-durlobactam therapy with source control and flap coverage was successful in treating the infection. Laboratory investigation revealed cefiderocol resistance mediated by ISAba36 insertion into the siderophore receptor pirA.
Keywords:
Acinetobacter baumannii; ISAba36; OXA-72; carbapenem resistance; cefiderocol; sulbactam-durlobactam.
MeSH terms
-
Acinetobacter Infections* / drug therapy
-
Acinetobacter Infections* / microbiology
-
Acinetobacter baumannii* / drug effects
-
Acinetobacter baumannii* / genetics
-
Anti-Bacterial Agents* / pharmacology
-
Azabicyclo Compounds / pharmacology
-
Bacterial Outer Membrane Proteins
-
Carbapenems* / pharmacology
-
Cefiderocol*
-
Cephalosporins* / pharmacology
-
DNA Transposable Elements / genetics
-
Drug Resistance, Multiple, Bacterial / genetics
-
Humans
-
Male
-
Microbial Sensitivity Tests*
-
Receptors, Cell Surface / genetics
-
Receptors, Cell Surface / metabolism
-
Sulbactam / pharmacology
Substances
-
Cefiderocol
-
Anti-Bacterial Agents
-
Cephalosporins
-
Carbapenems
-
Receptors, Cell Surface
-
siderophore receptors
-
Sulbactam
-
durlobactam
-
Azabicyclo Compounds
-
DNA Transposable Elements
-
Bacterial Outer Membrane Proteins